See more : Network18 Media & Investments Limited (NETWORK18.NS) Income Statement Analysis – Financial Results
Complete financial analysis of 4SC AG (VSC.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 4SC AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Nandan Denim Limited (NDL.BO) Income Statement Analysis – Financial Results
- Qinqin Foodstuffs Group (Cayman) Company Limited (QQFSF) Income Statement Analysis – Financial Results
- Wee-Cig International Corporation (WCIG) Income Statement Analysis – Financial Results
- Wuhan Golden Laser Co., Ltd (300220.SZ) Income Statement Analysis – Financial Results
- PBG S.A. (PBG.WA) Income Statement Analysis – Financial Results
4SC AG (VSC.DE)
About 4SC AG
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 304.00K | 436.00K | 14.11M | 2.25M | 2.20M | 4.17M | 4.20M | 2.06M | 2.30M | 7.06M | 4.90M | 4.35M |
| Cost of Revenue | 95.00K | 155.00K | 383.00K | 519.00K | 345.00K | 343.00K | 574.00K | 76.00K | 1.11M | 4.08M | 1.47M | 327.00K |
| Gross Profit | 209.00K | 281.00K | 13.73M | 1.73M | 1.85M | 3.83M | 3.62M | 1.98M | 1.19M | 2.98M | 3.43M | 4.03M |
| Gross Profit Ratio | 68.75% | 64.45% | 97.29% | 76.95% | 84.29% | 91.78% | 86.32% | 96.31% | 51.74% | 42.17% | 69.94% | 92.49% |
| Research & Development | 0.00 | 0.00 | 0.00 | 18.47M | 13.65M | 18.55M | 12.01M | 11.48M | 6.44M | 8.74M | 10.64M | 13.35M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 2.43M | 2.73M | 2.72M | 2.79M | 3.38M | 2.88M | 3.12M | 3.31M | 3.92M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 411.00K | 408.00K | 408.00K | 351.00K | 410.00K | 348.00K | 846.00K | 503.00K | 597.00K |
| SG&A | 2.39M | 3.51M | 4.75M | 2.84M | 3.14M | 3.12M | 3.14M | 3.79M | 3.23M | 3.97M | 3.81M | 4.51M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.59M | 14.64M | 23.36M | 20.81M | 15.67M | 21.39M | 14.56M | 13.29M | 9.03M | 12.38M | 14.01M | 17.36M |
| Cost & Expenses | 8.69M | 14.80M | 23.74M | 21.33M | 16.02M | 21.74M | 15.14M | 13.36M | 10.14M | 16.46M | 15.48M | 17.69M |
| Interest Income | 159.00K | 0.00 | 3.00K | 85.00K | 34.00K | 0.00 | 13.00K | 19.00K | 0.00 | 0.00 | 52.00K | 128.00K |
| Interest Expense | 0.00 | 682.00K | 0.00 | 0.00 | -34.00K | -1.00K | 0.00 | 0.00 | -346.00K | -225.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 531.00K | 620.00K | 851.00K | 138.00K | 118.00K | 109.00K | 167.00K | 161.00K | 158.00K | 354.00K | 360.00K | 380.00K |
| EBITDA | -7.90M | -13.06M | -7.39M | -19.42M | -13.76M | -17.45M | -10.81M | -12.24M | -7.84M | -9.08M | -10.25M | -13.00M |
| EBITDA Ratio | -2,597.04% | -2,995.18% | -52.39% | -862.48% | -626.55% | -418.09% | -257.52% | -594.22% | -341.64% | -128.75% | -208.99% | -298.67% |
| Operating Income | -8.43M | -13.68M | -8.24M | -19.56M | -13.88M | -17.56M | -10.98M | -12.40M | -8.00M | -9.44M | -10.61M | -13.38M |
| Operating Income Ratio | -2,771.71% | -3,137.39% | -58.42% | -868.61% | -631.92% | -420.70% | -261.50% | -602.04% | -348.52% | -133.76% | -216.33% | -307.40% |
| Total Other Income/Expenses | 204.00K | -682.00K | -1.39M | 573.00K | 21.00K | -9.00K | 48.00K | 1.12M | -186.00K | -189.00K | 84.00K | 174.00K |
| Income Before Tax | -8.22M | -14.36M | -9.63M | -18.99M | -13.86M | -17.57M | -10.93M | -11.28M | -8.19M | -9.63M | -10.53M | -13.21M |
| Income Before Tax Ratio | -2,704.60% | -3,293.81% | -68.24% | -843.16% | -630.97% | -420.92% | -260.35% | -547.77% | -356.62% | -136.44% | -214.62% | -303.40% |
| Income Tax Expense | 15.00K | 682.00K | 0.00 | 0.00 | 106.00K | 94.00K | 33.00K | 71.00K | 40.00K | 70.00K | 0.00 | 10.00K |
| Net Income | -8.24M | -14.36M | -9.63M | -18.99M | -13.96M | -17.66M | -10.96M | -11.36M | -8.23M | -9.70M | -10.53M | -13.22M |
| Net Income Ratio | -2,709.54% | -3,293.81% | -68.24% | -843.16% | -635.79% | -423.17% | -261.14% | -551.21% | -358.36% | -137.43% | -214.62% | -303.63% |
| EPS | -0.81 | -1.42 | -0.95 | -2.05 | -2.04 | -2.88 | -2.23 | -2.99 | -2.87 | -4.79 | -5.22 | -7.16 |
| EPS Diluted | -0.81 | -1.42 | -0.95 | -2.05 | -2.04 | -2.88 | -2.23 | -2.99 | -2.87 | -4.79 | -5.22 | -7.16 |
| Weighted Avg Shares Out | 10.11M | 10.11M | 10.13M | 9.27M | 6.85M | 6.13M | 4.91M | 3.79M | 2.87M | 2.03M | 2.01M | 1.85M |
| Weighted Avg Shares Out (Dil) | 10.11M | 10.11M | 10.13M | 9.27M | 6.85M | 6.13M | 4.91M | 3.79M | 2.87M | 2.03M | 2.01M | 1.85M |
Source: https://incomestatements.info
Category: Stock Reports